Faldaprevir plus pegyliertes Interferon alpha-2a und Ribavirin (PR) bei Patienten mit HIV und Hepatitis C Genotyp (GT)-1 Koinfektion: End of Treatment Response (ETR) – Ergebnisse der Phase III Studie STARTVerso 4

2014 ◽  
Vol 52 (01) ◽  
Author(s):  
P Ingiliz ◽  
JK Rockstroh ◽  
M Nelson ◽  
V Soriano ◽  
K Arastéh ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Treatment Response ◽  
Interferon Alpha ◽  
Phase Iii ◽  
End Of Treatment

scholarly journals Response to combination of sofosbuvir and daclatasvir in chronic hepatitis C infection.

2020 ◽  
Vol 27 (12) ◽  
pp. 2596-2600
Author(s):  
Irfan Ahmad ◽  
Muhammad Israr ul Haq ◽  
Ghulam Abbas
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Treatment Response ◽  
Chronic Hepatitis C ◽  
Hepatitis C Infection ◽  
Open Label ◽  
College Hospital ◽  
End Of Treatment ◽  
Significant Difference ◽  
Chronic Hepatitis C Patients

Objectives: To determine efficacy of sofosbuvir and daclatasvir in the treatment of chronic hepatitis C infection. Study Design: Open label uncontrolled interventional study. Setting: Hepatitis Clinic, Sheikh Zayed Medical College/Hospital, Rahim Yar Khan. Period: June to December 2018. Material & Methods: Five hundred treatment naïve chronic hepatitis C patients including those with compensated cirrhosis were included in the study. They were given sofosbuvir 400 mg daily and daclatasvir 60 mg daily. Weight based ribavirin was added if patient has evidence of cirrhosis. Treatment duration was 12 weeks for non-cirrhotic and 24 weeks for cirrhotics. End of treatment response (ETR) was recorded. Results: Mean age of the included patients was 41±11.69 with range from 8 to 82 years, while 217 (43.4 %) patients were male and 283 (56.6 %) were female. Cirrhosis was present in 59 (11.8 %) patients; among these 35.6 % were in Child A and 64.4 % in early Child B. End of treatment response occurred in 491 (98.2 %) patients and there was no significant difference in ETR between male and female patients, and between cirrhotic and non-cirrhotic. Similarly, there was no significant difference in age between those having ETR and those having no ETR. Fatigue was experienced by 13.2 % and headache by 4.2 % patients. Conclusion: The combination of sofosbuvir and daclatasvir has high response rate in chronic hepatitis C patients of our population.

African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians

2001 ◽  
Vol 8 (4) ◽  
pp. 264-269 ◽  
Author(s):  
J. L. Kinzie ◽  
P. H. Naylor ◽  
M. G. Nathani ◽  
R. R. Peleman ◽  
M. N. Ehrinpreis ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
African Americans ◽  
Treatment Response ◽  
Chronic Hepatitis C ◽  
Genotype 1 ◽  
End Of Treatment

scholarly journals Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response

2010 ◽  
Vol 25 (5) ◽  
pp. 957-963 ◽  
Author(s):  
Su Rin Shin ◽  
Dong Hyun Sinn ◽  
Geum-Youn Gwak ◽  
Moon Seok Cho ◽  
Joon Hyoek Lee ◽  
...  
Keyword(s):  
Risk Factors ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Treatment Response ◽  
Chronic Hepatitis C ◽  
End Of Treatment ◽  
Chronic Hepatitis C Patients

scholarly journals Change in hepatitis C virus genotype in hemodialysis patients after end-of-treatment response to interferon monotherapy—relapse or re-infection?

2007 ◽  
Vol 80 (1) ◽  
pp. 80-86 ◽  
Author(s):  
Teresa C. Arrais ◽  
Sonia Van Dooren ◽  
Anne-Mieke Vandamme ◽  
Christian Brechot ◽  
Francois Rimlinger ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Response ◽  
Hemodialysis Patients ◽  
Virus Genotype ◽  
Interferon Monotherapy ◽  
End Of Treatment

scholarly journals Elderly Patients Are at Greater Risk of Cytopenia During Antiviral Therapy for Hepatitis C

2006 ◽  
Vol 20 (9) ◽  
pp. 589-592 ◽  
Author(s):  
CG Nudo ◽  
P Wong ◽  
N Hilzenrat ◽  
M Deschênes
Keyword(s):  
Hepatitis C ◽  
Elderly Patients ◽  
Antiviral Therapy ◽  
Treatment Response ◽  
The Elderly ◽  
Control Group ◽  
Younger Patients ◽  
Dose Modification ◽  
End Of Treatment ◽  
Chronic Hcv

The results of antiviral therapy for hepatitis C virus (HCV) have improved recently with the use of pegylated interferon (PEG-IFN)/ribavirin (RBV) combination therapy. At this point, most patients with chronic HCV remain untreated. Thus, it is anticipated that therapy will be more appealing and prescribed more broadly than in the past, including in patients considered marginal.AIM: To examine the effects of PEG-IFN-based antiviral therapy in elderly patients with chronic HCV.METHODS: The charts of patients treated with chronic HCV were reviewed. Patients were defined as elderly if they were 60 years of age or older. The control group consisted of patients younger than 60 years of age who were matched to the treated elderly patients based on sex, treating physician, prescribed treatment and intended prescribed treatment duration. The data recorded included end of treatment response, sustained virological response (SVR), adverse events, dose modification and withdrawal of therapy.RESULTS: Thirty of 147 (20.4%) elderly patients attending a hepatitis C clinic were treated. The average age of the elderly patients was 65±4 years. Forty-three per cent were men and 57% were women. Ten per cent received IFN monotherapy, 70% received a combination of IFN/RBV therapy and 20% received a combination of PEG-IFN/RBV therapy. The overall response rates in the elderly patients compared with the younger patients was 46.7% versus 65.8% (P=0.11) for end of treatment response and 33.3% versus 51.2% (P=0.13) for SVR. The rate of dose modification was 50% in the elderly patients compared with 29% in the control group (P=0.08). Therapy was discontinued in 53% of the elderly compared with 34% of younger patients (P=0.17). The younger patients reported more side effects than elderly patients; although, there were more laboratory abnormalities (anemia, thrombocytopenia and neutropenia) in the elderly patients during therapy than in the younger group (0.93 per patient versus 0.49 per patient, P=0.01).CONCLUSION: Elderly patients with chronic HCV can be treated successfully. However, they are more at risk to develop cytopenias while on treatment. In such patients, the close monitoring of blood counts is necessary. Larger studies are needed to confirm these findings and to determine whether SVR differs in this population.

scholarly journals Hepatitis C reinfection in former and active injecting drug users in Belgium

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Dana Busschots ◽  
Rob Bielen ◽  
Özgür M. Koc ◽  
Leen Heyens ◽  
Rita Verrando ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Treatment Response ◽  
Drug Users ◽  
Meta Analysis ◽  
Hcv Rna ◽  
Genotype 3 ◽  
Reinfection Rate ◽  
Cross Sectional ◽  
End Of Treatment ◽  
Viral Hepatitis C

Abstract Background There is currently no systematic screening for hepatitis C (HCV) reinfection in people who inject drugs (PWID) after treatment in Belgium. However, in a recent meta-analysis, the overall HCV reinfection rate was 5.9/100 person-years (PY) among PWID. Accordingly, this study was undertaken to investigate the reinfection rate in former and active PWID who achieved the end of treatment response after direct-acting antiviral (DAA) treatment in Belgium. Methods This observational cross-sectional study recruited individuals with a history of injecting drug use who had achieved the end of treatment response to any DAA treatment between 2015 and 2020. Participants were offered a post-treatment HCV RNA test. Results Eighty-five potential participants were eligible to participate and contacted, of whom 60 participants were enrolled in the study with a median age of 51.0 (IQR 44.3–56.0) years; it was reported that 23.3% continued to inject drugs intravenously after DAA treatment. Liver cirrhosis was present in 12.9%. The majority had genotype 1a (51.7%) or genotype 3 (15.0%) infection. We detected no reinfections in this study population. The total time patients were followed up for reinfection in the study was 78.5 PY (median 1.0 years IQR 0.4–2.0). Conclusion Reinfection after successful treatment with DAA initially appears to be very low in Belgian PWID. Therefore, efforts should be made to screen individuals with persistent risk behaviors for reinfection systematically. In addition, a national HCV registry should be established to accurately define the burden of HCV infection and reinfection in Belgium and support the elimination of viral hepatitis C in Europe. Trial registration clinicaltrials.gov NCT04251572, Registered 5 Feb 2020–Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04251572.

Sign in / Sign up

Export Citation Format

Share Document